Research articles
ScienceAsia 49 (2023):ID 899-909 |doi:
10.2306/scienceasia1513-1874.2023.100
Silencing circRNA TLK1 reduces endothelial cell injury in
coronary heart disease
Jian Lia, Zhu Zhuob, Zhen Renc, GaiXia Lid,*
ABSTRACT: Circular RNAs (circRNAs) play important roles in the progression of many diseases including coronary
heart disease (CHD), one of the leading causes of heart-related death worldwide. This study aimed to investigate the
effect and mechanism of circTLK1 on vascular endothelial cell injury by targeting the miR-374a-5p/FOXO1 axis. Here,
oxidized low-density lipoprotein (ox-LDL)-treated HUVECs and HFD-fed ApoE?/?C57BL/6J mice were used as in vitro
and in vivo models, and the expression levels of circTLK1, miR-374a-5p, and FOXO1 were examined by RT-qPCR or
Western blot analysis. CircTLK1 and FOXO1 were found to be increased in blood of patients with coronary heart disease
and ox-LDL-induced HUVECs, while miR-374a-5p was decreased. Silencing circTLK1 attenuated endothelial cell injury
and atherosclerosis development in vitro and in vivo. miR-374a-5p can be sponged by circTLK1, and miR-374a-5p
inhibitor can abolish the therapeutic effect of silencing circTLK1 on endothelial cell injury. In addition, miR-374a-5p
bound to FOXO1, which mediated the therapeutic effect of circTLK1 silencing on vascular endothelial cell injury. Taken
together, circTLK1 silencing reduces endothelial cell injury in CHD by targeting FOXO1 with miR-374a-5p, suggesting
that circTLK1 may be a new target for CHD treatment.
Download PDF
29 Downloads 504 Views
a |
Department of Internal Medicine, Qingdao Shinan District People?s Hospital, Qingdao City, Shandong 266005 China |
b |
Department of Cardiology, Linyi Third People?s Hospital, Linyi City, Shandong 276023 China |
c |
Department of Nursing, Qingdao Shinan District People?s Hospital, Qingdao City, Shandong 266005 China |
d |
Department of ECG Room, Qingdao Women and Children Hospital, Qingdao City, Shandong 266034 China |
* Corresponding author, E-mail: ligaixia@stu-edu.cn
Received 16 Feb 2023, Accepted 31 Oct 2023
|